Profile data is unavailable for this security.
About the company
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). It also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for acne as well as inflammatory bowel diseases (HT-003). Its development products include HT-001, HT-KIT, HT-ALZ, and HT-TBI. Its BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The Company also has interests in certain other assets being developed by third parties including a treatment for patients with lupus.
- Revenue in USD (TTM)0.00
- Net income in USD-7.46m
- Incorporated2017
- Employees2.00
- LocationHoth Therapeutics Inc590 Madison Avenue, 21St FloorNEW YORK 10022United StatesUSA
- Phone+1 (646) 756-2997
- Websitehttps://hoththerapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tian'an Pharmaceutical Co Ltd | 10.65m | 3.14m | 4.16m | -- | 0.0232 | 0.005 | 1.14 | 0.3906 | 0.2246 | 0.2246 | 0.7611 | 1.03 | -- | -- | -- | -- | -- | -- | -- | -- | 68.54 | -- | 29.51 | -- | 13.36 | 25.66 | 0.00 | -- | 50.51 | -- | 106.71 | -- | -- | -- |
| Healthy Extracts Inc | 2.88m | -1.37m | 5.18m | -- | -- | 12.94 | -- | 1.80 | -0.4725 | -0.4725 | 0.9845 | 0.1336 | 1.12 | 0.6654 | 28.03 | -- | -53.40 | -53.78 | -168.81 | -146.65 | 67.83 | 45.68 | -47.73 | -87.53 | 0.2059 | -0.9153 | 0.7131 | -- | 10.41 | 105.93 | -151.54 | -- | -- | -- |
| Biofrontera Inc | 35.24m | -13.51m | 5.22m | 85.00 | -- | 0.4397 | -- | 0.1481 | -5.29 | -5.29 | 12.12 | 2.14 | 1.21 | 1.97 | 7.27 | 414,623.50 | -46.20 | -- | -113.24 | -- | 47.75 | -- | -38.33 | -- | 1.46 | -3.53 | 0.0264 | -- | 18.82 | -- | -3,045.47 | -- | -- | -- |
| Sunshine Biopharma Inc | 32.96m | -4.23m | 5.26m | 44.00 | -- | 0.2101 | -- | 0.1596 | -144.23 | -144.23 | 95.92 | 12.52 | 1.14 | 3.18 | 12.55 | 749,079.60 | -14.65 | -101.52 | -17.57 | -137.04 | 30.78 | 35.47 | -12.82 | -165.33 | 3.57 | -- | 0.00 | -- | 454.42 | -- | 83.15 | -- | 110.99 | -- |
| Sentient Brands Holdings Inc | 0.00 | -954.07k | 5.37m | 2.00 | -- | -- | -- | -- | -0.0164 | -0.0164 | 0.00 | -0.0307 | 0.00 | 0.00 | -- | 0.00 | -460.67 | -220.36 | -- | -- | -- | 41.81 | -- | -31,451.19 | 0.0015 | -2.50 | -- | -- | -73.68 | -- | 34.98 | -- | -- | -- |
| Silo Pharma Inc | 72.12k | -3.45m | 5.52m | 3.00 | -- | 0.7682 | -- | 76.48 | -1.16 | -1.18 | 0.0242 | 1.60 | 0.0079 | -- | -- | 24,040.00 | -37.69 | -24.90 | -43.50 | -26.39 | 91.90 | 82.79 | -4,777.02 | -2,757.85 | -- | -- | 0.00 | -- | 0.00 | -- | 7.07 | -- | -- | -- |
| Universe Pharmaceuticals Inc | 26.73m | -18.55m | 5.52m | 225.00 | -- | 0.0318 | -- | 0.2064 | -5.10 | -5.10 | 7.35 | 7.34 | 0.4462 | 6.13 | 1.68 | 118,781.90 | -30.97 | 5.31 | -48.85 | 7.07 | 28.27 | 46.26 | -69.40 | 6.25 | 1.46 | -0.6939 | 0.1958 | 0.00 | -19.52 | 2.53 | 29.46 | -- | -21.17 | -- |
| AgriFORCE Growing Systems Ltd | 57.60k | -15.05m | 5.56m | 7.00 | -- | 0.353 | -- | 96.56 | -5.81 | -5.81 | 0.0037 | 0.1343 | 0.0034 | -- | 1.21 | 8,228.57 | -88.79 | -78.95 | -124.14 | -109.86 | 17.86 | -- | -26,121.49 | -243,182.50 | 1.24 | -1.28 | 0.0789 | -- | -- | -- | 8.85 | -- | 48.61 | -- |
| Bon Natural Life Ltd | 25.56m | 2.47m | 5.88m | 96.00 | 0.5646 | 0.057 | 1.56 | 0.2299 | 2.62 | 2.62 | 22.95 | 25.95 | 0.5254 | 11.40 | 2.94 | 266,207.70 | 4.95 | 14.04 | 6.59 | 20.68 | 27.75 | 30.00 | 9.42 | 17.62 | 2.32 | 16.88 | 0.1438 | 0.00 | -1.29 | 22.32 | -26.32 | 83.09 | -6.70 | -- |
| Hoth Therapeutics Inc | 0.00 | -7.46m | 6.21m | 2.00 | -- | 0.5158 | -- | -- | -1.69 | -1.69 | 0.00 | 1.74 | 0.00 | -- | -- | 0.00 | -67.99 | -157.07 | -76.33 | -177.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 31.01 | -- | -- | -- |
| GT Biopharma Inc | 0.00 | -11.35m | 6.84m | 2.00 | -- | 1.24 | -- | -- | -7.72 | -7.72 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -82.84 | -205.36 | -120.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 63.62 | -- | -- | -- |
| Evoke Pharma Inc | 7.53m | -6.53m | 7.43m | 4.00 | -- | 1.38 | -- | 0.9873 | -16.23 | -16.23 | 11.24 | 3.63 | 0.7128 | 0.4307 | 4.97 | 1,881,428.00 | -61.83 | -100.48 | -136.53 | -151.10 | 96.97 | -- | -86.75 | -480.52 | 1.22 | -19.91 | 0.6523 | -- | 106.51 | -- | 5.25 | -- | -- | -- |
| CV Sciences Inc | 15.85m | -2.53m | 8.29m | 42.00 | -- | 3.31 | -- | 0.5233 | -0.0157 | -0.0157 | 0.098 | 0.0139 | 1.69 | 1.55 | 25.35 | 377,285.70 | -26.94 | -43.42 | -73.44 | -77.75 | 46.06 | 51.81 | -15.95 | -45.68 | 0.2530 | -- | 0.0114 | -- | -1.24 | -19.80 | 133.96 | -20.87 | -- | -- |
| Coeptis Therapeutics Holdings Inc | 0.00 | -16.14m | 8.35m | 5.00 | -- | -- | -- | -- | -0.5143 | -0.5143 | 0.00 | -0.0111 | 0.00 | -- | -- | 0.00 | -284.35 | -37.29 | -709.12 | -38.23 | -- | -- | -- | -- | -- | -- | 1.22 | -- | -- | -- | 43.40 | -- | -- | -- |
Data as of Nov 13 2024. Currency figures normalised to Hoth Therapeutics Inc's reporting currency: US Dollar USD
5.05%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 30 Jun 2024 | 213.00k | 3.09% |
| UBS Securities LLCas of 30 Jun 2024 | 41.21k | 0.60% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 38.80k | 0.56% |
| Geode Capital Management LLCas of 30 Jun 2024 | 35.66k | 0.52% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024 | 10.01k | 0.15% |
| Tower Research Capital LLCas of 30 Jun 2024 | 7.53k | 0.11% |
| UBS Financial Services, Inc.as of 30 Jun 2024 | 2.15k | 0.03% |
| Brewin Dolphin Wealth Management Ltd.as of 30 Jun 2024 | 240.00 | 0.00% |
| Qube Research & Technologies Ltd.as of 30 Jun 2024 | 100.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 30 Jun 2024 | 35.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
